About Synlogic Therapeutics
Synlogic Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2013 by James J Collins. Engineered microbes are developed as programmable therapeutics for metabolic disorders. Synlogic Therapeutics has raised $34.4 million across 9 funding rounds from investors including Gates Foundation, HHS and Orbimed. The company has 1 employees. Synlogic Therapeutics offers products and services including Synthetic Biotics. Its focus areas include Life Sciences, Genomics, Applied Genomics and Synthetic Biology. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Synlogic Therapeutics was founded in 2013 in Cambridge, Massachusetts, within the biotechnology sector. A proprietary platform is employed to engineer microbes for drug production, targeting urea cycle disorders and phenylketonuria. Standardized interchangeable parts and gene-circuit controls are integrated to design synthetic biology solutions. Microbes are transformed into symbiotic living therapeutics that respond to pathophysiological signals in the human body, facilitating targeted treatments.
- Annual Revenue$8 K (USD)-99.76as on Dec 31, 2024
- Net Profit-$23.36 M (USD)61.88as on Dec 31, 2024
- EBITDA-$14.48 M (USD)70.96as on Dec 31, 2024
- Total Equity Funding$34.4M (USD)
in 9 rounds
- Latest Funding Round$80M (USD), Post-IPO
Jun 2019
- InvestorsGates Foundation
& 11 more
- Employee Count1
Products & Services of Synlogic Therapeutics
Synlogic Therapeutics offers a comprehensive portfolio of products and services, including Synthetic Biotics.
Engineered microbes to treat metabolic diseases like PKU.
Apps and channels of Synlogic Therapeutics
its YouTube channel Synlogic has 46 subscribers.
Funding Insights of Synlogic Therapeutics
Synlogic Therapeutics has successfully raised a total of $34.4M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $80 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $34.4M
- Total Rounds 9
- Last Round Post-IPO — $80M
- First Round $287,270
(Jul 2013)
- Investors Count 12
All 9 funding rounds of Synlogic Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | $80M | Post-IPO | – | – | – |
| May 2017 | $42M | Post-IPO | – | – | |
| Feb 2016 | $40M | Post-IPO | – | – | |
| Oct 2014 | $5M | Series A | – | Gates Foundation | |
| Sep 2014 | $113,864 | Grant | – | – | |
| Sep 2013 | $299,999 | Grant | – | – | |
| Sep 2013 | $282,967 | Grant | – | – | |
| Jul 2013 | $29.4M | Series A | – | – | |
| Jul 2013 | $287,270 | Grant | – | – |
12 investors in total: 12 institutional.
Investors in Synlogic Therapeutics
Synlogic Therapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Gates Foundation, HHS and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investment, VC & financial advisory firm | 1974 | ajuib.co.kr | Seoul, South Korea | |
Private equity and hedge fund investments in healthcare are managed. | ally-bridge.com | Hong Kong, China | ||
VC Firm investing in geographies such as the US | cli.ventures | Palo Alto, United States | ||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
| arctic.com |
Investor details for Synlogic Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Synlogic Therapeutics
24 people are tracked at Synlogic Therapeutics (9 in leadership, 12 in board & advisors, 3 in team); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
James J Collins | Co-Founder | Leadership |
Mary Beth Dooley | Vice President, Head Of Finance | Leadership |
Antoine Awad | COO | Leadership |
Caroline B. Kurtz | Chief Development Officer | Leadership |
Roberto Vincent | Director Clinical Operations | Leadership |
Brendan St. Amant | Head, Legal | Leadership |
Steven Kates | VP, Regulatory Affairs | Leadership |
Ajay Munshi | Vp, Head, Corporate Development | Leadership |
Kevin Kesper | Head Of Manufacturing And Ms&t | Leadership |
Nick Leschly | Director | Board & advisors |
Patricia N. Hurter | Director | Board & advisors |
Tim Lu | Advisor | Board & advisors |
Jim Collins | Advisor | Board & advisors |
Ed Mathers | Director | Board & advisors |
Peter Barrett | Director | Board & advisors |
Michael Heffernan | Director | Board & advisors |
Lisa Kelly-Croswell | Director | Board & advisors |
Richard P. Shea | Director | Board & advisors |
Kristala Prather | Advisor | Board & advisors |
Christopher Voigt | Advisor | Board & advisors |
4 more people are available in the full profile.
Complete people profiles for Synlogic Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Synlogic Therapeutics
Synlogic Therapeutics is a publicly listed company on the NASDAQ with ticker symbol SYBX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Jun 2016
- Listed onNASDAQ: SYBX
- Listed entitySynlogic, Inc.
- Exchange sectorHealth technology
- ISINUS87166L2097
- Share price$0.56 (-50% on the day) · 2026-01-21
- Market capitalisation$6.6M
- EPS (diluted, trailing year)$-0.27
- Volume (last session)3,573,263
- Analyst consensusNeutral
Financials of Synlogic Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $8,000 | -$23.4M | -$14.5M |
| 2023 | $3.4M | -$61.3M | -$49.9M |
| 2022 | $1.2M | -$66.2M | -$61.8M |
| 2021 | $1.8M | -$60.6M | -$56.2M |
| 2020 | $545,000 | -$59.2M | -$56.1M |
Detailed financial statements for Synlogic Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Synlogic Therapeutics
4 dated milestones of Synlogic Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Synlogic Therapeutics is founded.
- Funding First funding round of $287K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $80.0M.
Competitors of Synlogic Therapeutics
Synlogic Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Synlogic Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Synlogic Therapeutics
The website of Synlogic Therapeutics (synlogictx.com) receives about 1.8K visits a month and ranks #6,942,794 among all websites worldwide, #6,833 in Biotechnology and Pharmaceuticals.
- Monthly visits1.8K
▼ 21.5% vs previous month
- Global rank#6,942,794
among all websites
- Category rank#6,833
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.8
- Average visit43 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with Synlogic Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| fiercebiotech.com | 100% | 858.3K | #81,022 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Synlogic Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Synlogic Therapeutics
Complete news archive for Synlogic Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synlogic Therapeutics
Synlogic Therapeutics was founded in 2013.
Synlogic Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Synlogic Therapeutics is a funded company, having raised a total of $34.4M across 9 funding rounds to date. The company's 1st funding round was a Grant of $287.27K, raised on Jul 2013.
Synlogic Therapeutics has 1 employees.
Annual revenue of Synlogic Therapeutics is $8K as on Dec 31, 2024.
Synlogic Therapeutics was founded in 2013 in Cambridge, Massachusetts, within the biotechnology sector. A proprietary platform is employed to engineer microbes for drug production, targeting urea cycle disorders and phenylketonuria. Standardized interchangeable parts and gene-circuit controls are integrated to design synthetic biology solutions. Microbes are transformed into symbiotic living therapeutics that respond to pathophysiological signals in the human body, facilitating targeted treatments.
Synlogic Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Synlogic Therapeutics offers Synthetic Biotics.
Yes, Synlogic Therapeutics is publicly traded on NASDAQ under the ticker symbol SYBX.
Synlogic Therapeutics has 12 investors. Key investors include Gates Foundation, HHS, Orbimed, Atlas Venture, and Perceptive Advisors.